V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20215258 | 20081410 | 1.7 | 58.9 | Palliative (P) | 2016-11-12 | 2016-11-12 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100417018 |
| 20215259 | 20081411 | null | 76.8 | Palliative (P) | 2018-01-22 | 2018-01-23 | LANREOTIDE | 02 | N | LANREOTIDE | 100088862 |
| 20215260 | 20081412 | 1.78 | 65.2 | Curative (C) | 2017-05-31 | 2017-06-25 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101816024 |
| 20215262 | 20081413 | 1.6 | 94.8 | Palliative (P) | 2017-11-25 | 2017-12-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100027391 |
| 20215265 | 20081414 | 1.66 | 83 | Palliative (P) | 2017-05-25 | 2017-06-02 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100272429 |
| 20215266 | 20081415 | 1.83 | 75.3 | null | 2018-12-13 | 2018-12-30 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100084391 |
| 20215270 | 20081416 | 1.7 | 66.3 | Palliative (P) | 2019-05-04 | 2019-05-19 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100347596 |
| 20215271 | 20081417 | 1.75 | 0 | Curative (C) | 2018-03-28 | 2018-04-18 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100286930 |
| 20215272 | 20081418 | 1.75 | 79 | Palliative (P) | null | 2016-11-14 | HCX (Cape + Cisp + Tras) - Load | 02 | N | IMATINIB | 100371361 |
| 20215273 | 20081419 | 1.76 | 0 | Palliative (P) | 2017-10-29 | 2017-10-29 | LANREOTIDE | 02 | N | LANREOTIDE | 100072315 |
| 20215275 | 20081421 | 1.89 | 93.45 | Curative (C) | 2018-02-23 | 2018-02-28 | FLUOROURACIL + MITOMYCIN + RT | N | null | FLUOROURACIL + MITOMYCIN + RT | 100897031 |
| 20215276 | 20081422 | 1.59 | 63 | Curative (C) | 2017-02-18 | 2017-02-27 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101214701 |
| 20215277 | 20081423 | 1.7 | 68.8 | Palliative (P) | 2019-06-14 | 2019-06-17 | Trial Unspecified | Y | N | TRIAL | 101208264 |
| 20215278 | 20081424 | 1.67 | 0 | Palliative (P) | 2020-06-29 | 2020-07-01 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100168435 |
| 20215280 | 20081425 | 1.56 | null | Palliative (P) | 2019-07-01 | 2019-07-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100568913 |
| 20215281 | 20081426 | 1.52 | 132 | null | 2017-01-23 | 2017-02-10 | FLUOROURACIL + MITOMYCIN + RT | N | null | FLUOROURACIL + MITOMYCIN + RT | 100433127 |
| 20215282 | 20081427 | 1.76 | null | Curative (C) | 2018-02-18 | 2018-03-05 | Fluorouracil+Mitomycin+RT (Anal Ca) | 2 | null | FLUOROURACIL + MITOMYCIN + RT | 101620680 |
| 20215283 | 20081428 | 1.89 | 71.8 | Curative (C) | 2017-08-10 | 2017-08-25 | Trial Unspecified | Y | Y | TRIAL | 101863621 |
| 20215284 | 20081429 | 1.8 | null | Curative (C) | 2017-10-31 | 2017-11-28 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | null | FLUOROURACIL + MITOMYCIN + RT | 101692849 |
| 20215287 | 20081430 | 1.72 | 98.9 | null | 2019-12-22 | 2020-01-11 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | TRIAL | 101558037 |
| 20215288 | 20081431 | 1.79 | 89 | null | 2015-10-21 | 2015-10-23 | LANREOTIDE | N | null | LANREOTIDE | 100241114 |
| 20215289 | 20081432 | 1.67 | 83.65 | Palliative (P) | 2017-05-18 | 2017-06-03 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101488446 |
| 20215290 | 20081433 | 1.75 | 46.8 | Palliative (P) | 2018-03-14 | 2018-03-14 | Trial Unspecified | Y | N | TRIAL | 101052951 |
| 20215292 | 20081434 | 1.63 | 45.5 | 03 | 2018-12-17 | 2018-12-25 | HCX (Cape + Cisp + Tras) - Load | 02 | N | IMATINIB | 100837498 |
| 20215294 | 20081436 | 1.73 | 88.7 | Palliative (P) | 2019-06-19 | 2019-07-02 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101140458 |
| 20215295 | 20081437 | 1.57 | null | null | 2017-06-19 | 2017-06-29 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | IMATINIB | 101035202 |
| 20215296 | 20081438 | 1.56 | 76.5 | Palliative (P) | 2016-11-25 | 2016-12-23 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100967309 |
| 20215299 | 20081440 | 1.75 | 46.8 | Palliative (P) | 2017-07-14 | 2017-07-16 | Imatinib 400mg | 02 | N | IMATINIB | 101097894 |
| 20215300 | 20081441 | null | null | null | 2020-05-12 | 2020-05-22 | LANREOTIDE | 02 | null | LANREOTIDE | 100337322 |
| 20215301 | 20081442 | 1.63 | 58.8 | Palliative (P) | 2018-02-05 | 2018-02-19 | Cape+Cisplatin+Trastuzumab Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101231578 |
| 20215304 | 20081443 | 1.7 | 72.2 | Curative (C) | 2016-07-22 | 2016-07-22 | FLUOROURACIL + MITOMYCIN + RT | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 100735680 |
| 20215305 | 20081444 | 1.67 | 83.5 | Curative (C) | 2018-10-08 | 2018-10-24 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101694657 |
| 20215306 | 20081445 | 1.65 | 72 | Palliative (P) | 2019-04-16 | 2019-05-05 | Trial Unspecified | Y | N | TRIAL | 100856600 |
| 20215307 | 20081446 | 1.85 | 116.7 | Not known (9) | 2018-05-02 | 2018-05-24 | FLUOROURACIL + MITOMYCIN + RT | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101182137 |
| 20215308 | 20081447 | null | 65.5 | Palliative (P) | 2017-05-13 | 2017-06-13 | LANREOTIDE | 02 | N | LANREOTIDE | 100658126 |
| 20215310 | 20081448 | null | 64 | 03 | 2021-01-19 | 2021-01-20 | LANREOTIDE | 02 | N | LANREOTIDE | 100641010 |
| 20215311 | 20081449 | 1.76 | 74.1 | null | 2016-09-11 | 2016-10-21 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101352791 |
| 20215314 | 20081450 | 1.5 | 0 | Palliative (P) | 2018-02-12 | 2018-02-18 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101646859 |
| 20215317 | 20081453 | null | 100.7 | Curative (C) | 2016-08-14 | 2016-08-15 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100633123 |
| 20215318 | 20081454 | null | 70.7 | null | 2017-05-04 | 2017-05-06 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 101365667 |
| 20215319 | 20081455 | 1.67 | null | Neo-adjuvant (N) | 2016-02-21 | 2016-02-21 | Trial Unspecified | Y | N | TRIAL | 100558155 |
| 20215320 | 20081456 | 1.53 | 73.6 | Curative (C) | 2016-06-10 | 2016-07-01 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101471011 |
| 20215321 | 20081457 | 0 | 50 | Neo-adjuvant (N) | 2018-07-19 | 2018-07-19 | Trial Unspecified | 01 | N | TRIAL | 101380522 |
| 20215322 | 20081458 | 1.64 | 0 | Palliative (P) | 2016-06-16 | 2016-07-01 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100848124 |
| 20215324 | 20081460 | 1.62 | 92.35 | null | 2018-05-10 | 2018-05-10 | FLUOROURACIL + MITOMYCIN + RT | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 100686775 |
| 20215325 | 20081461 | 1.55 | null | Palliative (P) | 2017-06-23 | 2017-07-11 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101268619 |
| 20215327 | 20081462 | 1.64 | null | Curative (C) | null | 2019-10-10 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100229588 |
| 20215328 | 20081463 | 1.54 | 74 | Palliative (P) | 2018-02-15 | 2018-03-03 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100874783 |
| 20215329 | 20081464 | 1.73 | 60 | Palliative (P) | 2017-10-23 | 2017-11-09 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101630768 |
| 20215330 | 20081465 | 1.73 | 78.5 | Palliative (P) | 2016-07-26 | 2016-07-30 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101179107 |